IDEAYA Biosciences, Inc.
IDYA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$34.71
KIRA · Stoqly’s AI analyst, in plain words
- IDEAYA Biosciences, Inc. had $219M of revenue in fiscal 2025, up 3,024.4% on the year before. Over five years, revenue changed +62.1% a year on average.
- Its operating margin was −72.8%, up 4,598.2 pts: of every 100 in sales, about −73 is left after running the business.
- IDEAYA Biosciences, Inc. lost $114M in fiscal 2025.
- Free cash flow was −$73.5M in fiscal 2025, −33.6% of revenue.
Market cap
$3.2B
P/E
—
Revenue
$219M
Net income
−$114M
Free cash flow
−$73.5M
Operating margin
−72.8%
IDEAYA Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+3,024.4%
Yes. Sales grew 3,024.4% last year.
Does it make a profit?
−52.0%
No. It lost money last year.
Does profit turn into cash?
−33.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What IDEAYA Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- IDEAYA Biosciences, Inc.
- CIK
- 0001676725
IDEAYA Biosciences, Inc. · IDYA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $27.9M | $50.9M | $23.4M | $7.0M | $219M |
| Revenue growth | 43.0% | 82.3% | −54.1% | −70.1% | 3,024.4% |
| Operating margin | −179.9% | −122.7% | −574.9% | −4,671.1% | −72.8% |
| Net income | −$49.8M | −$58.7M | −$113M | −$274M | −$114M |
| Net margin | −178.1% | −115.2% | −483.0% | −3,921.1% | −52.0% |
| Diluted EPS | −$1.41 | −$1.42 | −$1.96 | −$3.36 | −$1.28 |
| Cash | |||||
| Cash from operations | −$55.8M | −$87.2M | −$115M | −$248M | −$71.1M |
| Capital expenditure | $2.6M | $3.4M | $2.4M | $3.9M | $2.4M |
| Free cash flow | −$58.4M | −$90.6M | −$118M | −$251M | −$73.5M |
| FCF margin | −209.1% | −177.9% | −502.9% | −3,592.0% | −33.6% |
| Share count change | 42.6% | 17.6% | 38.8% | 42.0% | 8.3% |
| Debt and strength | |||||
| Cash and short-term investments | $247M | $365M | $525M | $676M | $639M |
| Shareholders' equity | $302M | $349M | $621M | $1.1B | $1.0B |
| Current ratio | 5.6x | 11.7x | 19.7x | 15.0x | 11.3x |
| Returns and quality | |||||
| Return on equity | −19.9% | −18.0% | −23.3% | −32.7% | −10.9% |
| Return on tangible equity | −16.5% | −16.8% | −18.2% | −25.9% | −11.1% |
| Piotroski F-score | 1 | 2 | 1 | 1 | 3 |
| Altman Z'' | 5.1 | 12.2 | 25.1 | 17.1 | 12.9 |
Insiders bought, 12 months
$1.6M
1 insider
Insiders sold, 12 months
$1.4M
2 insiders
Of sales under plans
100%
$1.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
IDEAYA Biosciences, Inc. · IDYA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $34.71 a share, the company is worth $3.2B.
Source: SEC EDGAR XBRL filings (CIK 0001676725). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.